Table 1.
EC50 (µg/mL) of PG9 and PG16 IgG binding to synthetic ZM109/CAP45 glycopeptides and scaffolded V1V2 domains
| Abs | ZM-GP1 | ZM-GP2 | ZM-GP3 | ZM-GP4 | ZM-GP5 | ZM-GP6 | ZM-GP7 | ZM-GP8 | 1FD6 ZM109 V1V2 |
|---|---|---|---|---|---|---|---|---|---|
| PG9 | -- | 0.41 (2.7 nM) |
-- | -- | 0.34 (2.3 nM) |
0.008 (0.05 nM) |
-- | 0.24 (1.6 nM) |
0.1* (0.7 nM) |
| PG16 | -- | -- | -- | -- | -- | 0.22 (1.5 nM) |
-- | -- | 3.4* (23 nM) |
| Abs | CAP-GP1 | CAP-GP2 | CAP-GP3 | CAP-GP4 | CAP-GP5 | CAP-GP6 | CAP-GP7 | CAP-GP8 | 1FD6 CAP45 V1V2 |
|---|---|---|---|---|---|---|---|---|---|
| PG9 | -- | 0.27 (1.8 nM) |
-- | -- | 0.75 (5.0 nM) |
0.027 (0.18 nM) |
-- | 3.3 (22 nM) |
0.2* (1.4 nM) |
| PG16 | -- | -- | -- | -- | -- | 19.0 (126 nM) |
-- | -- | 9.1* (61 nM) |
“--“, no binding at 20 µg/mL;
*
adapted from ref. 13